Race And Clinical Outcomes In The Rxponder Trial

Race and clinical outcomes in the RxPONDER trial

Race, Ethnicity, and Clinical Outcomes From the TAILORx Trial

Racial inequities in breast cancer outcomes and tumor biology in RxPONDER

The RxPONDER trial and its impact on best clinical practice

RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer

Racial differences in the breast tumor microenvironment

TAILORx: Patient-Reported Outcomes in Breast Cancer

Dr. Albain Discusses Race-Based Breast Cancer Study Within TAILORx

Survival for Early Stage Breast Cancer Varies by Race and Ethnicity

Kalinsky discusses results from RxPONDER breast cancer clinical trial

Winship Cancer Institute of Emory University

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC

Important lessons from TAILORX, MINDACT and RX-PONDER:

Dr Richard De Boer discusses the TAILORx trial of OncotypeDX

Breast Cancer Network Australia

Adjuvant Therapy | 2023 Best of Breast Conference

Total Health | Oncology

Oncotype DX Breast Recurrence Score Assay after TAILORx and RxPONDER: What’s Next?

אונקוטסט

SABCS highlights: RxPONDER

Genomic predictors for treatment selection in ER+ breast cancer: TAILORx, MINDACT, and RxPONDER

Race and Prostate Cancer Disparities

University of California Television (UCTV)

N9831 trial: genes associated with early and late recurrence in HER2+ breast cancer

Providing Predictive and Prognostic Biomarkers for Breast Cancer From the TAILORx Trial

Targeted Oncology